Voclosporin coated coronary stent implanted in first patient

    EDMONTON, June 11 /CNW/ - Isotechnika Inc. announced today that its
partner, Atrium Medical Corporation has begun enrollment for their CONFIRM 1,
First-in-Man (FIM) drug eluting coronary stent clinical trial evaluating
Atrium's CINATRA(TM) voclosporin coated coronary stent system.
    This First-in-Man trial is a prospective, multi-center, single blind,
randomized, controlled study using the CINATRA(TM) voclosporin coated coronary
stent system, which will be compared to Atrium's CINATRA(TM) bare metal
coronary stent (BMS) platform. This first use study of voclosporin on an
implantable medical device will enroll 100 patients, and will be conducted at
seven hospitals in Belgium with Glenn Van Langenhove, MD, PhD of Middelheim
Hospital, Antwerp, as the study's Principal Investigator. The primary endpoint
of the trial is to evaluate the safety and performance of the CINATRA(TM)
voclosporin coated coronary stent system in patients with de novo coronary
artery disease. Patient outcomes, in addition to drug coated stent
performance, will be assessed by measuring Late Lumen Loss, in-stent and
in-segment lumen loss measurements at six months following implantation.
    "After many years of pre-clinical testing, Atrium is very excited to be
able to study the new CINATRA(TM) coronary stent platform with voclosporin, a
promising new drug, and the company's all natural O3FA coating technology that
merges the desirable safety benefits of a bare metal stent with the clinical
advantages of a bio-absorbable Omega 3 fatty acid coating," stated Trevor
Carlton, Atrium's Medical Corporation President. "Use of Atrium's patented
Omega 3 coating platform, together with its novel drug compound has created a
new class of patient treatment options that require a drug eluting coronary
stent. Interventional cardiologists and patients alike have been waiting for a
new technology that delivers the effectiveness of a drug eluting stent with a
safer, more natural, non-polymer coating platform resulting in a well healed
implant shortly after insertion."

    About CINATRA(TM) Voclosporin Coated Coronary Stent System
    The CINATRA(TM) Voclosporin Coated Coronary Stent System is comprised of
a cobalt chromium bare metal stent mounted on a delivery balloon catheter. The
stent and the balloon are coated with Atrium's proprietary Omega-3 fatty acid
coating technology utilizing voclosporin for its anti-inflammatory properties.

    About Isotechnika Inc.
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors such as voclosporin by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LX211 by Lux) for the treatment of uveitis.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com.

    About Atrium
    Atrium's vast expertise in medical device technologies for the treatment
of cardiovascular disease, hernia and adhesion prevention has brought a number
of breakthrough advances in several diversified healthcare markets including
interventional cardiology and radiology, chest trauma care and thoracic
drainage, vascular surgery, and soft tissue repair. Maintaining a commitment
to the latest ISO13485 Quality Standards, state-of-the-art manufacturing and
automation, cell biology and biomaterial discovery programs, Atrium continues
to excel in those healthcare segments that require more advanced surgical
intervention for improvements in patient outcome. For more information, call
800-370-7899 or visit www.atriummed.com.

    Forward-Looking Statements
    This press release may contain forward-looking statements. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, events or developments to be
materially different from any future results, events or developments expressed
or implied by such forward-looking statements. Forward-looking statements,
including the Company's belief as to the potential of its products, the
Company's expectations regarding the issuance of additional patents and the
Company's ability to protect its intellectual property, involve known and
unknown risks and uncertainties, which could cause the Company's actual
results to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, securing and maintaining
corporate alliances, the need for additional capital and the effect of capital
market conditions and other factors on capital availability, the ability to
economically manufacture its products, the potential of its products, the
success and timely completion of clinical studies and trials, the Company's
ability to successfully commercialize its products, competition, the ability
of the Company to defend its patents from infringement by third parties, and
the risk that the Company's patents may be subsequently shown to be invalid or
infringe the patents of others. Additional risks and uncertainties relating to
the Company and its business can be found in the "Risk Factors" section of the
Company's Annual Information Form. These factors should be considered
carefully and readers are cautioned not to place undue reliance on such
forward-looking statements.

    %SEDAR: 00010508E

For further information:

For further information: Dr. Robert Foster, Chairman & CEO, Isotechnika
Inc., Phone: (780) 487-1600 Ext.272, Fax: (780) 484-4105, Email:
rfoster@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 487-1600 Ext. 243, Fax: (780)
484-4105, E-mail: sgillis-paulgaard@isotechnika.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890